Tier 1 — highest
Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
Nutrients
2023
15(3):718
Bibliography
- PubMed
- PMID 36771424
- PubMed Central
- PMC9920098
- Funding
- Supported by the Ministry of Agriculture of the Czech Republic (QK1910264) and Ministry of Health of the Czech Republic (RVO-VFN-64165/2012).
- Competing interests
- Ladislav Jílek was a co-owner of Pure Food Norway, a food-supplement business. The paper states that this ownership and the funders had no role in study design, data collection/analysis, interpretation, manuscript writing or publication decision.
Study snapshot
| Design | Prospective randomized double-blind placebo-controlled trial |
|---|---|
| Model | Children aged 3-7 years with autism spectrum disorder |
| Sample | 40 randomized; 28 completed |
| Intervention | Sulforaphane versus placebo with assessments at baseline, 18 weeks and 36 weeks. |
| Duration | 36 weeks |
| Endpoints | Aberrant Behavior Checklist; Social Responsiveness Scale-2; Autism Diagnostic Observation Schedule-2; Tolerability |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Sulforaphane & Autism: What RCTs and the 2025 Meta-Analyses ShowSulforaphane autism evidence reconciled: positive, mixed and null randomized trials plus two 2025 meta-analyses with differing pooled conclusions, doses, safety and limitations.Read analysis
- Sulforaphane Benefits: Human Evidence Ranked by Strength (2026)Sulforaphane benefits ranked by human evidence across 37 papers: bioavailability, pollutant biomarkers, blood sugar, autism, NRF2, H. pylori, cancer and key limitations.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
